Core Insights - Gilead Sciences has agreed to acquire the remaining stake in development partner Arcellx, valuing the biotechnology company at approximately $7.8 billion upon closing [1] Company Summary - The acquisition signifies Gilead Sciences' commitment to expanding its portfolio in the biotechnology sector [1] - Arcellx is positioned to enhance Gilead's capabilities in developing innovative therapies [1]

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.By [Callum Keown]ShareResize---ReprintsIn this ...

每经AI快讯，2月23日，吉利德科学公司盘前股价下跌1.3%。 ...

每经AI快讯，2月23日，Arcellx美股盘前涨超76%，吉利德科学公司将以每股115美元的价格收购 Arcellx。 ...

Core Viewpoint - Gilead Sciences, Inc. has announced a definitive agreement to acquire Arcellx for an implied equity value of $7.8 billion, which includes $115 per share in cash and a contingent value right of $5 per share [1] Company Overview - Gilead Sciences is a biopharmaceutical company focused on innovative medicines for life-threatening diseases, including cancer, with a commitment to advancing public health [12] - Arcellx is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other incurable diseases [11] Transaction Details - The acquisition is expected to close in the second quarter of 2026, pending customary closing conditions and regulatory approvals [7] - Gilead currently owns approximately 11.5% of Arcellx's outstanding common stock [7] - The offer price represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of February 20, 2026 [8] Product Pipeline - Gilead and Arcellx are collaborating on anitocabtagene autoleucel (anito-cel), a CAR T-cell therapy for multiple myeloma, which has shown deep and durable responses in clinical studies [2][3] - The Biologics License Application (BLA) for anito-cel has been accepted by the FDA, with a Prescription Drug User Fee Act (PDUFA) action date set for December 23, 2026 [4] Strategic Importance - Gilead's CEO emphasized the potential of anito-cel to become a foundational treatment for multiple myeloma and its importance in the company's oncology and inflammation efforts [5] - Arcellx's D-Domain CAR technology platform offers proprietary target-binding domains that could enhance future CAR T-cell and bispecific therapies [5] Financial Implications - The transaction is expected to be accretive to Gilead's earnings per share in 2028 and beyond, contingent upon FDA approval of anito-cel [9]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. Barclays Takes Neutral Stance on Gilead Sciences (GILD) Despite Strategic Refocus On February 20, Barclays began coverage of Gilead Sciences, Inc. (NASDAQ:GILD) with an Equal Weight rating. The firm set a $155 price target on the stock. The firm said the company is returning its focus to what it has historically done well, developing treatments for infectious diseases. Still, Barclays believes the stock a ...

Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company adopts a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned and novice investors [1] Company Mission - The mission of Allka Research is to empower individuals financially by sharing knowledge and insights through platforms like Seeking Alpha [1] - The company aims to provide thought-provoking analyses and informed perspectives to foster a community of informed investors [1] - Allka Research seeks to demystify investing, inspiring confidence in readers to navigate the markets intelligently [1]

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as a leading immunotherapy stock by hedge funds, reporting strong fiscal Q4 and full year 2025 results, driven by the growth of Biktarvy, Descovy, and the launch of Yeztugo, the first twice-yearly HIV prevention therapy in the country [1] Financial Performance - Total fiscal Q4 revenues increased by 5% to $7.9 billion compared to the previous year, primarily due to higher sales of HIV and Liver Disease products, although this was partially offset by lower sales of Veklury® [2] Analyst Ratings - Following the earnings release, several analysts updated their ratings for Gilead. Needham raised the price target to $170 from $140 while maintaining a Buy rating, and Scotiabank increased its target to $177 from $140, keeping an Outperform rating [3] - BofA also raised its price target to $162 from $154, maintaining a Buy rating, and expressed confidence in the company's growth for 2026 based on strong fiscal Q4 performance [4] Company Overview - Gilead Sciences, Inc. is a biotech company focused on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that addresses unmet medical needs [5]